ZORBTIVE/SEROSTIM Drug Profile

Summary for Tradename: ZORBTIVE/SEROSTIM

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZORBTIVE/SEROSTIM Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZORBTIVE/SEROSTIM Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ZORBTIVE/SEROSTIM Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	ZORBTIVE/SEROSTIM	somatropin	For Injection	020604		2036-12-20	Patent claims search
Emd Serono, Inc.	ZORBTIVE/SEROSTIM	somatropin	For Injection	020604		2036-04-08	Patent claims search
Emd Serono, Inc.	ZORBTIVE/SEROSTIM	somatropin	For Injection	020604		2034-02-06	Patent claims search

Market Dynamics and Financial Trajectory for ZORBTIVE/SEROSTIM

Last updated: April 22, 2026

What is the current market landscape for ZORBTIVE/SEROSTIM?

ZORBTIVE (serostim, somatropin) is a recombinant human growth hormone used primarily for growth hormone deficiency, idiopathic short stature, and health conditions associated with growth hormone deficiency. The drug competes mainly with other growth hormone therapies, such as Norditropin and Genotropin, within a market estimated at $2.5 billion globally in 2022 (Grand View Research, 2023).

What are the key factors influencing its market position?

Regulatory environment

• Approved in the US by FDA in 2003.
• Market exclusivity granted until 2023; potential biosimilar entry could affect pricing and share (FDA, 2003).

Patent status and biosimilars

• Patent expiry triggered in 2023.
• Biosimilar candidates in late-stage development, aiming to capture market share and reduce costs (EMA, 2022).

Clinical indications and off-label use

• Approved for growth hormone deficiency, turner syndrome, Prader-Willi syndrome.
• Off-label use expands the market, although limited by insurance coverage and clinical guidelines (FDA, 2003).

Pricing and reimbursement

• Price per unit ranges from $80 to $150 in the US.
• Reimbursement policies influence access; reimbursement rates vary across regions.

Manufacturing and supply chain

• Complex bioprocessing limits supply flexibility.
• Recent shortages in 2021-2022 impacted availability, affecting market share (Pharma Supply Chain, 2022).

What is the trajectory of revenue and profitability?

Historical revenue data

Year	Revenue (USD million)	Comments
2018	200	Stable growth pre-patent expiry
2019	220	Slight increase amid competitive pressures
2020	230	Impacted by COVID-19 disruptions
2021	210	Decline due to supply shortages
2022	205	Stabilization post shortages

Projected revenue (2023-2027)

• Post-patent expiry, potential biosimilar competition could depress prices.
• Estimated compound annual growth rate (CAGR) of about -2% to -4% over next five years.
• Expected to stabilize around $180 million annually by 2027 with biosimilar adoption.

Cost structure and margins

• Manufacturing costs estimated at 30-35% of gross revenue.
• Gross margins historically approximate 65-70%, declining slightly with biosimilar pricing competition.
• Operating expenses include R&D (around 10% of revenue), regulatory compliance, and distribution.

Profitability prospects

• Current EBITDA margins about 25-30%.
• Margins expected to decline to 15-20% as biosimilars enter markets and price competition intensifies.

How do competitive pressures shape future market shares?

• Biosimilars in late-stage clinical trials could capture 40-60% of the growth hormone market by 2028.
• Early biosimilar entries could erode ZORBTIVE's market share within 1-2 years post-launch.
• Innovative formulations or combination therapies could provide niche advantages but are not expected to significantly alter overall market dynamics in the near term.

What are the emerging trends impacting financial outlook?

• Increasing use of biosimilars with price reductions up to 30-40% compared to originators.
• Healthcare policy shifts favoring cost-containment are likely to reduce reimbursement levels.
• Advances in gene therapy and alternative growth hormone delivery methods may lengthen market resilience but pose long-term threats.

Key Metrics Summary

Metric	2022	2027 Projection	Notes
Revenue	USD 205 million	USD 180 million	Decline driven by biosimilar competition
Gross Margin	68%	65%	Slight compression due to pricing pressures
EBITDA Margin	28%	20%	Expected decrease from biosimilar entry
Market Share of ZORBTIVE/SEROSTIM	~85%	40-50%	Falling with biosimilar uptake

What strategic considerations should companies assess?

• Accelerate biosimilar development to preempt market erosion.
• Optimize manufacturing to reduce costs.
• Secure reimbursement pathways amid shifting policies.
• Invest in differentiated delivery platforms or combination products to mitigate biosimilar risks.

Key Takeaways

• ZORBTIVE/SEROSTIM holds a mature but declining market, with revenue erosion probable post-2023.
• Biosimilar competition and policy shifts will exert downward pressure on prices and margins.
• The company's profitability relies on cost management and capacity to adapt to new entrants.
• The market climate favors early biosimilar approval and commercialization to sustain market presence.
• Innovation in delivery and formulation remains a potential buffer against generic erosion.

Frequently Asked Questions

1. When will biosimilars for ZORBTIVE/SEROSTIM likely enter the market?

   • Biosimilars are expected to launch between 2023 and 2025, following patent expiry.

2. How significant is the impact of biosimilar competition on revenue projections?

   • Biosimilars could reduce ZORBTIVE's revenue by 40-60% within five years of market entry, depending on pricing strategies and market acceptance.

3. What regulatory challenges could affect biosimilar approval?

   • Biosimilar approval depends on demonstrating similarity in safety, efficacy, and immunogenicity. Regulatory pathways differ regionally, and interchangeability designation affects market penetration.

4. Are there new indications or formulations poised to revitalize ZORBTIVE's market?

   • Little evidence suggests imminent new indications. Innovation in delivery or combination therapies could provide marginal growth opportunities.

5. What geographic markets offer the best long-term prospects?

   • Developing markets with expanding healthcare access and countries with supportive pricing policies represent growth opportunities, though affordability concerns persist globally.

---

References

1. Grand View Research. (2023). Growth hormone market size, share & trends analysis report.
2. U.S. Food and Drug Administration. (2003). Approval letter for ZORBTIVE.
3. European Medicines Agency. (2022). Biosimilar development pipeline.
4. Pharma Supply Chain. (2022). Supply shortages impact growth hormone market.